MFA
XFOR icon

Mayflower Financial Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Mayflower Financial Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-333
Closed -$17K – 366
2022
Q3 		$17K Hold
333
– – ﹤0.01% 330
2022
Q2 		$10K Hold
333
– – ﹤0.01% 334
2022
Q1 		$18K Hold
333
– – ﹤0.01% 358
2021
Q4 		$23K Buy
+333
New +$42.1K ﹤0.01% 343

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Mayflower Financial Advisors's XFOR Position: Q4 2022 in Review

Mayflower Financial Advisors sold out of X4 Pharmaceuticals (XFOR) in Q4 2022, closing a stake of 333 shares — an estimated $17K sold.

Mayflower Financial Advisors first reported a position in XFOR in Q4 2021 and held it in 4 quarters. The position peaked at $23K in Q4 2021. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2022.

  • Mayflower Financial Advisors reported no remaining X4 Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Mayflower Financial Advisors sold 333 X4 Pharmaceuticals shares in Q4 2022, an estimated $17K.
  • Mayflower Financial Advisors first reported a position in X4 Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Mayflower Financial Advisors's X4 Pharmaceuticals position peaked at $23K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2022.

Based on Mayflower Financial Advisors's 13F filing for Q4 2022, filed 19 Jan 2023.